Concord Biotech has successfully completed regulatory inspections at its Unit-II Formulation Facility, conducted by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda. The inspection took place from June 18, 2026 to June 24, 2026. This milestone strengthens the company's global manufacturing footprint and regulatory standing in key African markets.

Regulatory Inspection Details

The successful completion of these inspections underscores Concord Biotech's adherence to international pharmaceutical manufacturing and quality standards. The key details of the regulatory assessments are outlined below:

Significance of the Development

The clearance from both the Kenyan and Ugandan drug regulatory authorities reflects the company's commitment to maintaining robust quality and compliance frameworks at its formulation manufacturing unit. Approvals from the PPB and the NDA are essential for market access and product distribution in Kenya and Uganda, respectively, and are recognized as credible regulatory benchmarks within the African pharmaceutical landscape.

This successful inspection outcome at the Unit-II Formulation Facility positions Concord Biotech to strengthen its regulatory standing across key African markets, reinforcing its presence in the region's pharmaceutical sector.

Concord Biotech has agreed to acquire a 27.38% equity stake in FSGE Renewable Power Private Limited for ₹6.3 crore to develop a wind-solar hybrid power project. The investment aims to supply renewable energy to the company's Limbasi Facility in Gujarat, featuring a wind capacity of approximately 6.3 MW AC and a solar capacity of approximately 6.3 MWp DC. This transition to renewable energy is intended to reduce the company's carbon footprint and lower long-term energy costs, reinforcing its commitment to environmental responsibility and operational efficiency.

The acquisition will be made through a cash consideration of ₹6.3 crore, to be paid in one or more tranches. Following the acquisition, FSGE will become an associate of Concord Biotech Limited, categorizing the investment as a Related Party Transaction. The company confirmed that the transaction will be conducted at arm's length, and none of the promoter, promoter group, or group companies hold any interest in the target entity.

FSGE Renewable Power Private Limited was incorporated on August 19, 2023, as a Special Purpose Vehicle for captive power generation through renewable energy. The entity has not yet commenced commercial operations. Its authorized and paid-up share capital stands at ₹1,00,000, divided into 10,000 equity shares of ₹10 each as on June 15, 2026.

Transaction Details

The requisite details regarding the acquisition have been submitted to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The equity shares against the current investment are expected to be allotted within 60 days from the date of the agreement.